Jonathan Kimmelman
McGill University
H-index: 45
North America-Canada
Top articles of Jonathan Kimmelman
The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials: A Systematic Review and Meta-analysis
2024/4/30
The impact of feedback training on prediction of cancer clinical trial results
Clinical Trials
2024/4
Jeffrey Peppercorn
H-Index: 36
Jonathan Kimmelman
H-Index: 30
Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies
JCO Oncology Practice
2024/2
Jonathan Kimmelman
H-Index: 30
Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis
Clinical Trials
2024/1/29
Merlin Bittlinger
H-Index: 7
Jonathan Kimmelman
H-Index: 30
Varieties of community uncertainty and clinical equipoise
Kennedy Institute of Ethics Journal
2023
Alex John London
H-Index: 23
Jonathan Kimmelman
H-Index: 30
Predicting Clinical Trial Results: A Synthesis of Five Empirical Studies and Their Implications
Perspectives in Biology and Medicine
2023
Jonathan Kimmelman
H-Index: 30
Timing for First-in-Minor Clinical Trials of New Cancer Drugs
The Journal of Pediatrics
2023/8/31
Contra el excepcionalismo en la investigación durante la pandemia1
A fondo
2023/10
Alex John London
H-Index: 23
Jonathan Kimmelman
H-Index: 30
Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study
Scientific Reports
2023/9/26
Catherine Wang
H-Index: 0
Jonathan Kimmelman
H-Index: 30
Matured forecast analyses for “systematic and narrative review lead experts to different cancer trial predictions”
2023/7/1
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials
2023/4/5
Merlin Bittlinger
H-Index: 7
Jonathan Kimmelman
H-Index: 30
Research Milestone Forecasting in Cystic Fibrosis
2023/1/13
Felix Ratjen
H-Index: 54
Jonathan Kimmelman
H-Index: 30
Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis
BMC Research Notes
2022/12/12
Jonathan Kimmelman
H-Index: 30
Marcin Waligora
H-Index: 11
Participant Recruitment From Low-and Middle-Income Countries for Pivotal Trials of Drugs Approved by the US Food and Drug Administration: A Cross-Sectional Analysis
Annals of Internal Medicine
2022/12
Jonathan Kimmelman
H-Index: 30
Clarifying the ethics and oversight of chimeric research
Hastings Center Report
2022/11
Ethical considerations for phase I trials in oncology
2022/10/20
Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study
Plos one
2022/9/12
Jonathan Kimmelman
H-Index: 30
Quantifying patient investment in novel neurological drug development
Neurotherapeutics
2022/9/1
Jonathan Kimmelman
H-Index: 30
Was the Lack of Efficacy of Trastuzumab in Low-her2 Breast Cancer Patients Foreseeable?
2022/8/26
Jonathan Kimmelman
H-Index: 30
The proportion of randomized controlled trials that inform clinical practice
Elife
2022/8/17
Jonathan Kimmelman
H-Index: 30
Co-Authors
